Titre : Sphingolipides

Sphingolipides : Questions médicales fréquentes

Termes MeSH sélectionnés :

Learning

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une maladie liée aux sphingolipides ?

Le diagnostic repose sur des tests génétiques, des analyses biochimiques et des biopsies.
Maladies métaboliques Sphingolipides
#2

Quels tests sont utilisés pour évaluer les sphingolipides ?

Des tests sanguins et des analyses d'urine mesurent les niveaux de sphingolipides.
Analyse sanguine Sphingolipides
#3

Les symptômes peuvent-ils indiquer un déséquilibre des sphingolipides ?

Oui, des symptômes neurologiques ou cutanés peuvent signaler un déséquilibre.
Symptômes neurologiques Sphingolipides
#4

Quelle imagerie est utile pour les maladies des sphingolipides ?

L'IRM et la TDM peuvent aider à visualiser les effets des maladies sur les organes.
Imagerie par résonance magnétique Sphingolipides
#5

Les antécédents familiaux sont-ils importants pour le diagnostic ?

Oui, les antécédents familiaux peuvent indiquer une prédisposition génétique aux maladies.
Antécédents familiaux Sphingolipides

Symptômes 5

#1

Quels sont les symptômes des troubles liés aux sphingolipides ?

Les symptômes incluent des troubles neurologiques, des problèmes cutanés et des douleurs.
Symptômes neurologiques Sphingolipides
#2

Les troubles digestifs sont-ils associés aux sphingolipides ?

Oui, certains troubles digestifs peuvent être liés à des anomalies des sphingolipides.
Troubles digestifs Sphingolipides
#3

Comment les sphingolipides affectent-ils le système nerveux ?

Ils jouent un rôle dans la myélinisation et la signalisation neuronale, affectant la fonction nerveuse.
Système nerveux Sphingolipides
#4

Les troubles de la peau sont-ils fréquents avec les sphingolipides ?

Oui, des affections cutanées comme l'eczéma peuvent être liées à des déséquilibres.
Affections cutanées Sphingolipides
#5

Les symptômes varient-ils selon le type de sphingolipide ?

Oui, les symptômes dépendent du type de sphingolipide impliqué et de l'organe affecté.
Types de sphingolipides Sphingolipides

Prévention 5

#1

Peut-on prévenir les maladies liées aux sphingolipides ?

La prévention est difficile, mais un mode de vie sain peut réduire les risques.
Prévention des maladies Sphingolipides
#2

Les tests génétiques aident-ils à la prévention ?

Oui, les tests génétiques peuvent identifier les personnes à risque et guider la prévention.
Tests génétiques Sphingolipides
#3

L'éducation sur les sphingolipides est-elle importante ?

Oui, comprendre les sphingolipides aide à reconnaître les symptômes et à agir rapidement.
Éducation à la santé Sphingolipides
#4

Les habitudes alimentaires influencent-elles la santé des sphingolipides ?

Oui, une alimentation équilibrée peut soutenir la santé des sphingolipides et prévenir des troubles.
Habitudes alimentaires Sphingolipides
#5

Les vaccinations peuvent-elles aider à prévenir des complications ?

Certaines vaccinations peuvent prévenir des infections qui aggravent les troubles liés aux sphingolipides.
Vaccination Sphingolipides

Traitements 5

#1

Quels traitements existent pour les maladies des sphingolipides ?

Les traitements incluent des thérapies enzymatiques, des médicaments et des soins symptomatiques.
Thérapie enzymatique Sphingolipides
#2

La diète peut-elle influencer les niveaux de sphingolipides ?

Oui, une alimentation riche en acides gras essentiels peut aider à réguler les sphingolipides.
Régime alimentaire Sphingolipides
#3

Les médicaments peuvent-ils réduire les symptômes ?

Oui, certains médicaments peuvent atténuer les symptômes et améliorer la qualité de vie.
Médicaments Sphingolipides
#4

Y a-t-il des traitements expérimentaux pour ces maladies ?

Oui, des essais cliniques explorent de nouvelles thérapies pour les troubles des sphingolipides.
Essais cliniques Sphingolipides
#5

La thérapie génique est-elle une option pour ces maladies ?

La thérapie génique est en recherche pour traiter certaines maladies liées aux sphingolipides.
Thérapie génique Sphingolipides

Complications 5

#1

Quelles complications peuvent survenir avec les troubles des sphingolipides ?

Les complications incluent des troubles neurologiques graves, des infections et des défaillances organiques.
Complications Sphingolipides
#2

Les troubles respiratoires sont-ils une complication possible ?

Oui, certains troubles des sphingolipides peuvent entraîner des complications respiratoires.
Troubles respiratoires Sphingolipides
#3

Comment les sphingolipides affectent-ils le cœur ?

Des déséquilibres peuvent contribuer à des maladies cardiovasculaires et à des arythmies.
Maladies cardiovasculaires Sphingolipides
#4

Les complications neurologiques sont-elles fréquentes ?

Oui, des complications comme la démence ou des troubles moteurs peuvent survenir.
Complications neurologiques Sphingolipides
#5

Les complications peuvent-elles être réversibles ?

Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles.
Réversibilité Sphingolipides

Facteurs de risque 5

#1

Quels sont les facteurs de risque pour les maladies des sphingolipides ?

Les facteurs incluent des antécédents familiaux, des mutations génétiques et des déséquilibres nutritionnels.
Facteurs de risque Sphingolipides
#2

L'âge influence-t-il le risque de troubles des sphingolipides ?

Oui, certains troubles apparaissent plus fréquemment chez les enfants ou les personnes âgées.
Âge Sphingolipides
#3

Les maladies auto-immunes sont-elles un facteur de risque ?

Oui, certaines maladies auto-immunes peuvent augmenter le risque de troubles liés aux sphingolipides.
Maladies auto-immunes Sphingolipides
#4

Le mode de vie influence-t-il le risque ?

Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque.
Mode de vie Sphingolipides
#5

Les infections peuvent-elles aggraver les troubles des sphingolipides ?

Oui, certaines infections peuvent exacerber les symptômes et les complications.
Infections Sphingolipides
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Sphingolipides : Questions médicales les plus fréquentes", "headline": "Sphingolipides : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Sphingolipides : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-13", "dateModified": "2025-03-10", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Sphingolipides" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Lipides membranaires", "url": "https://questionsmedicales.fr/mesh/D008563", "about": { "@type": "MedicalCondition", "name": "Lipides membranaires", "code": { "@type": "MedicalCode", "code": "D008563", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Glycosphingolipides", "alternateName": "Glycosphingolipids", "url": "https://questionsmedicales.fr/mesh/D006028", "about": { "@type": "MedicalCondition", "name": "Glycosphingolipides", "code": { "@type": "MedicalCode", "code": "D006028", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Glycosphingolipides acides", "alternateName": "Acidic Glycosphingolipids", "url": "https://questionsmedicales.fr/mesh/D020384", "about": { "@type": "MedicalCondition", "name": "Glycosphingolipides acides", "code": { "@type": "MedicalCode", "code": "D020384", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Gangliosides", "alternateName": "Gangliosides", "url": "https://questionsmedicales.fr/mesh/D005732", "about": { "@type": "MedicalCondition", "name": "Gangliosides", "code": { "@type": "MedicalCode", "code": "D005732", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ganglioside GM1", "alternateName": "G(M1) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005677", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM1", "code": { "@type": "MedicalCode", "code": "D005677", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.390" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM2", "alternateName": "G(M2) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005678", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM2", "code": { "@type": "MedicalCode", "code": "D005678", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.400" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM3", "alternateName": "G(M3) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005679", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM3", "code": { "@type": "MedicalCode", "code": "D005679", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.510" } } } ] }, { "@type": "MedicalWebPage", "name": "Ganglioside GM1", "alternateName": "G(M1) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005677", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM1", "code": { "@type": "MedicalCode", "code": "D005677", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.390" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM2", "alternateName": "G(M2) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005678", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM2", "code": { "@type": "MedicalCode", "code": "D005678", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.400" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM3", "alternateName": "G(M3) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005679", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM3", "code": { "@type": "MedicalCode", "code": "D005679", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.510" } } }, { "@type": "MedicalWebPage", "name": "Sulfoglycosphingolipides", "alternateName": "Sulfoglycosphingolipids", "url": "https://questionsmedicales.fr/mesh/D013433", "about": { "@type": "MedicalCondition", "name": "Sulfoglycosphingolipides", "code": { "@type": "MedicalCode", "code": "D013433", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.837" } } } ] }, { "@type": "MedicalWebPage", "name": "Gangliosides", "alternateName": "Gangliosides", "url": "https://questionsmedicales.fr/mesh/D005732", "about": { "@type": "MedicalCondition", "name": "Gangliosides", "code": { "@type": "MedicalCode", "code": "D005732", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Ganglioside GM1", "alternateName": "G(M1) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005677", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM1", "code": { "@type": "MedicalCode", "code": "D005677", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.390" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM2", "alternateName": "G(M2) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005678", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM2", "code": { "@type": "MedicalCode", "code": "D005678", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.400" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM3", "alternateName": "G(M3) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005679", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM3", "code": { "@type": "MedicalCode", "code": "D005679", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.510" } } } ] }, { "@type": "MedicalWebPage", "name": "Ganglioside GM1", "alternateName": "G(M1) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005677", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM1", "code": { "@type": "MedicalCode", "code": "D005677", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.390" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM2", "alternateName": "G(M2) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005678", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM2", "code": { "@type": "MedicalCode", "code": "D005678", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.400" } } }, { "@type": "MedicalWebPage", "name": "Ganglioside GM3", "alternateName": "G(M3) Ganglioside", "url": "https://questionsmedicales.fr/mesh/D005679", "about": { "@type": "MedicalCondition", "name": "Ganglioside GM3", "code": { "@type": "MedicalCode", "code": "D005679", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.475.510" } } }, { "@type": "MedicalWebPage", "name": "Sulfoglycosphingolipides", "alternateName": "Sulfoglycosphingolipids", "url": "https://questionsmedicales.fr/mesh/D013433", "about": { "@type": "MedicalCondition", "name": "Sulfoglycosphingolipides", "code": { "@type": "MedicalCode", "code": "D013433", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.025.837" } } }, { "@type": "MedicalWebPage", "name": "Glycosphingolipides neutres", "alternateName": "Neutral Glycosphingolipids", "url": "https://questionsmedicales.fr/mesh/D020383", "about": { "@type": "MedicalCondition", "name": "Glycosphingolipides neutres", "code": { "@type": "MedicalCode", "code": "D020383", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Céramides", "alternateName": "Ceramides", "url": "https://questionsmedicales.fr/mesh/D002518", "about": { "@type": "MedicalCondition", "name": "Céramides", "code": { "@type": "MedicalCode", "code": "D002518", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Cérébrosides", "alternateName": "Cerebrosides", "url": "https://questionsmedicales.fr/mesh/D002554", "about": { "@type": "MedicalCondition", "name": "Cérébrosides", "code": { "@type": "MedicalCode", "code": "D002554", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } } ] }, { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } }, { "@type": "MedicalWebPage", "name": "Globosides", "alternateName": "Globosides", "url": "https://questionsmedicales.fr/mesh/D005915", "about": { "@type": "MedicalCondition", "name": "Globosides", "code": { "@type": "MedicalCode", "code": "D005915", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.425" } } }, { "@type": "MedicalWebPage", "name": "Lactosylcéramides", "alternateName": "Lactosylceramides", "url": "https://questionsmedicales.fr/mesh/D007790", "about": { "@type": "MedicalCondition", "name": "Lactosylcéramides", "code": { "@type": "MedicalCode", "code": "D007790", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.612" } } }, { "@type": "MedicalWebPage", "name": "Trihexosylcéramide", "alternateName": "Trihexosylceramides", "url": "https://questionsmedicales.fr/mesh/D014281", "about": { "@type": "MedicalCondition", "name": "Trihexosylcéramide", "code": { "@type": "MedicalCode", "code": "D014281", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.906" } } } ] }, { "@type": "MedicalWebPage", "name": "Cérébrosides", "alternateName": "Cerebrosides", "url": "https://questionsmedicales.fr/mesh/D002554", "about": { "@type": "MedicalCondition", "name": "Cérébrosides", "code": { "@type": "MedicalCode", "code": "D002554", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } } ] }, { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } }, { "@type": "MedicalWebPage", "name": "Globosides", "alternateName": "Globosides", "url": "https://questionsmedicales.fr/mesh/D005915", "about": { "@type": "MedicalCondition", "name": "Globosides", "code": { "@type": "MedicalCode", "code": "D005915", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.425" } } }, { "@type": "MedicalWebPage", "name": "Lactosylcéramides", "alternateName": "Lactosylceramides", "url": "https://questionsmedicales.fr/mesh/D007790", "about": { "@type": "MedicalCondition", "name": "Lactosylcéramides", "code": { "@type": "MedicalCode", "code": "D007790", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.612" } } }, { "@type": "MedicalWebPage", "name": "Trihexosylcéramide", "alternateName": "Trihexosylceramides", "url": "https://questionsmedicales.fr/mesh/D014281", "about": { "@type": "MedicalCondition", "name": "Trihexosylcéramide", "code": { "@type": "MedicalCode", "code": "D014281", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.906" } } }, { "@type": "MedicalWebPage", "name": "Sphingomyéline", "alternateName": "Sphingomyelins", "url": "https://questionsmedicales.fr/mesh/D013109", "about": { "@type": "MedicalCondition", "name": "Sphingomyéline", "code": { "@type": "MedicalCode", "code": "D013109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.870" } } } ] }, { "@type": "MedicalWebPage", "name": "Céramides", "alternateName": "Ceramides", "url": "https://questionsmedicales.fr/mesh/D002518", "about": { "@type": "MedicalCondition", "name": "Céramides", "code": { "@type": "MedicalCode", "code": "D002518", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Cérébrosides", "alternateName": "Cerebrosides", "url": "https://questionsmedicales.fr/mesh/D002554", "about": { "@type": "MedicalCondition", "name": "Cérébrosides", "code": { "@type": "MedicalCode", "code": "D002554", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } } ] }, { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } }, { "@type": "MedicalWebPage", "name": "Globosides", "alternateName": "Globosides", "url": "https://questionsmedicales.fr/mesh/D005915", "about": { "@type": "MedicalCondition", "name": "Globosides", "code": { "@type": "MedicalCode", "code": "D005915", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.425" } } }, { "@type": "MedicalWebPage", "name": "Lactosylcéramides", "alternateName": "Lactosylceramides", "url": "https://questionsmedicales.fr/mesh/D007790", "about": { "@type": "MedicalCondition", "name": "Lactosylcéramides", "code": { "@type": "MedicalCode", "code": "D007790", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.612" } } }, { "@type": "MedicalWebPage", "name": "Trihexosylcéramide", "alternateName": "Trihexosylceramides", "url": "https://questionsmedicales.fr/mesh/D014281", "about": { "@type": "MedicalCondition", "name": "Trihexosylcéramide", "code": { "@type": "MedicalCode", "code": "D014281", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.906" } } } ] }, { "@type": "MedicalWebPage", "name": "Cérébrosides", "alternateName": "Cerebrosides", "url": "https://questionsmedicales.fr/mesh/D002554", "about": { "@type": "MedicalCondition", "name": "Cérébrosides", "code": { "@type": "MedicalCode", "code": "D002554", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } } ] }, { "@type": "MedicalWebPage", "name": "Galactosylcéramides", "alternateName": "Galactosylceramides", "url": "https://questionsmedicales.fr/mesh/D005699", "about": { "@type": "MedicalCondition", "name": "Galactosylcéramides", "code": { "@type": "MedicalCode", "code": "D005699", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.450" } } }, { "@type": "MedicalWebPage", "name": "Glucosylcéramides", "alternateName": "Glucosylceramides", "url": "https://questionsmedicales.fr/mesh/D005963", "about": { "@type": "MedicalCondition", "name": "Glucosylcéramides", "code": { "@type": "MedicalCode", "code": "D005963", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.250.490" } } }, { "@type": "MedicalWebPage", "name": "Globosides", "alternateName": "Globosides", "url": "https://questionsmedicales.fr/mesh/D005915", "about": { "@type": "MedicalCondition", "name": "Globosides", "code": { "@type": "MedicalCode", "code": "D005915", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.425" } } }, { "@type": "MedicalWebPage", "name": "Lactosylcéramides", "alternateName": "Lactosylceramides", "url": "https://questionsmedicales.fr/mesh/D007790", "about": { "@type": "MedicalCondition", "name": "Lactosylcéramides", "code": { "@type": "MedicalCode", "code": "D007790", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.612" } } }, { "@type": "MedicalWebPage", "name": "Trihexosylcéramide", "alternateName": "Trihexosylceramides", "url": "https://questionsmedicales.fr/mesh/D014281", "about": { "@type": "MedicalCondition", "name": "Trihexosylcéramide", "code": { "@type": "MedicalCode", "code": "D014281", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.200.906" } } }, { "@type": "MedicalWebPage", "name": "Sphingomyéline", "alternateName": "Sphingomyelins", "url": "https://questionsmedicales.fr/mesh/D013109", "about": { "@type": "MedicalCondition", "name": "Sphingomyéline", "code": { "@type": "MedicalCode", "code": "D013109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.612.870" } } }, { "@type": "MedicalWebPage", "name": "Psychosine", "alternateName": "Psychosine", "url": "https://questionsmedicales.fr/mesh/D011609", "about": { "@type": "MedicalCondition", "name": "Psychosine", "code": { "@type": "MedicalCode", "code": "D011609", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D10.570.877.360.806" } } } ] } ], "about": { "@type": "MedicalCondition", "name": "Sphingolipides", "alternateName": "Sphingolipids", "code": { "@type": "MedicalCode", "code": "D013107", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Erich Gulbins", "url": "https://questionsmedicales.fr/author/Erich%20Gulbins", "affiliation": { "@type": "Organization", "name": "Department of Molecular Biology, University of Duisburg-Essen, Essen, Germany." } }, { "@type": "Person", "name": "Giovanni D'Angelo", "url": "https://questionsmedicales.fr/author/Giovanni%20D%27Angelo", "affiliation": { "@type": "Organization", "name": "Interfaculty Institute of Bioengineering, Ecole polytechnique fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland giovanni.dangelo@epfl.ch Christopher.Clarke@stonybrookmedicine.edu lianacsilva@ff.ulisboa.pt." } }, { "@type": "Person", "name": "Anna Kovilakath", "url": "https://questionsmedicales.fr/author/Anna%20Kovilakath", "affiliation": { "@type": "Organization", "name": "Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, United States." } }, { "@type": "Person", "name": "L Ashley Cowart", "url": "https://questionsmedicales.fr/author/L%20Ashley%20Cowart", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry and Molecular Biology and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States." } }, { "@type": "Person", "name": "Tyrone Dowdy", "url": "https://questionsmedicales.fr/author/Tyrone%20Dowdy", "affiliation": { "@type": "Organization", "name": "Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Interactive Learning System for Learning Calculus.", "datePublished": "2024-03-11", "url": "https://questionsmedicales.fr/article/38765243", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.12688/f1000research.73595.2" } }, { "@type": "ScholarlyArticle", "name": "An empirical study on learners' learning emotion and learning effect in offline learning environment.", "datePublished": "2023-11-16", "url": "https://questionsmedicales.fr/article/37972001", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0294407" } }, { "@type": "ScholarlyArticle", "name": "The hard problem of meta-learning is what-to-learn.", "datePublished": "2024-09-23", "url": "https://questionsmedicales.fr/article/39311527", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1017/S0140525X24000268" } }, { "@type": "ScholarlyArticle", "name": "Describing movement learning using metric learning.", "datePublished": "2023-02-03", "url": "https://questionsmedicales.fr/article/36735670", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0272509" } }, { "@type": "ScholarlyArticle", "name": "Lifelong learning in community healthcare: Testing competence after learning activities in a blended learning space.", "datePublished": "2023-05-18", "url": "https://questionsmedicales.fr/article/37203208", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/scs.13180" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Lipides", "item": "https://questionsmedicales.fr/mesh/D008055" }, { "@type": "ListItem", "position": 3, "name": "Lipides membranaires", "item": "https://questionsmedicales.fr/mesh/D008563" }, { "@type": "ListItem", "position": 4, "name": "Sphingolipides", "item": "https://questionsmedicales.fr/mesh/D013107" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Sphingolipides - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Sphingolipides", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Sphingolipides", "description": "Comment diagnostiquer une maladie liée aux sphingolipides ?\nQuels tests sont utilisés pour évaluer les sphingolipides ?\nLes symptômes peuvent-ils indiquer un déséquilibre des sphingolipides ?\nQuelle imagerie est utile pour les maladies des sphingolipides ?\nLes antécédents familiaux sont-ils importants pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Learning#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Sphingolipides", "description": "Quels sont les symptômes des troubles liés aux sphingolipides ?\nLes troubles digestifs sont-ils associés aux sphingolipides ?\nComment les sphingolipides affectent-ils le système nerveux ?\nLes troubles de la peau sont-ils fréquents avec les sphingolipides ?\nLes symptômes varient-ils selon le type de sphingolipide ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Learning#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Sphingolipides", "description": "Peut-on prévenir les maladies liées aux sphingolipides ?\nLes tests génétiques aident-ils à la prévention ?\nL'éducation sur les sphingolipides est-elle importante ?\nLes habitudes alimentaires influencent-elles la santé des sphingolipides ?\nLes vaccinations peuvent-elles aider à prévenir des complications ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Learning#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Sphingolipides", "description": "Quels traitements existent pour les maladies des sphingolipides ?\nLa diète peut-elle influencer les niveaux de sphingolipides ?\nLes médicaments peuvent-ils réduire les symptômes ?\nY a-t-il des traitements expérimentaux pour ces maladies ?\nLa thérapie génique est-elle une option pour ces maladies ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Learning#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Sphingolipides", "description": "Quelles complications peuvent survenir avec les troubles des sphingolipides ?\nLes troubles respiratoires sont-ils une complication possible ?\nComment les sphingolipides affectent-ils le cœur ?\nLes complications neurologiques sont-elles fréquentes ?\nLes complications peuvent-elles être réversibles ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Learning#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Sphingolipides", "description": "Quels sont les facteurs de risque pour les maladies des sphingolipides ?\nL'âge influence-t-il le risque de troubles des sphingolipides ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe mode de vie influence-t-il le risque ?\nLes infections peuvent-elles aggraver les troubles des sphingolipides ?", "url": "https://questionsmedicales.fr/mesh/D013107?mesh_terms=Learning#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une maladie liée aux sphingolipides ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests génétiques, des analyses biochimiques et des biopsies." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les sphingolipides ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des analyses d'urine mesurent les niveaux de sphingolipides." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils indiquer un déséquilibre des sphingolipides ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes neurologiques ou cutanés peuvent signaler un déséquilibre." } }, { "@type": "Question", "name": "Quelle imagerie est utile pour les maladies des sphingolipides ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IRM et la TDM peuvent aider à visualiser les effets des maladies sur les organes." } }, { "@type": "Question", "name": "Les antécédents familiaux sont-ils importants pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les antécédents familiaux peuvent indiquer une prédisposition génétique aux maladies." } }, { "@type": "Question", "name": "Quels sont les symptômes des troubles liés aux sphingolipides ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles neurologiques, des problèmes cutanés et des douleurs." } }, { "@type": "Question", "name": "Les troubles digestifs sont-ils associés aux sphingolipides ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles digestifs peuvent être liés à des anomalies des sphingolipides." } }, { "@type": "Question", "name": "Comment les sphingolipides affectent-ils le système nerveux ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Ils jouent un rôle dans la myélinisation et la signalisation neuronale, affectant la fonction nerveuse." } }, { "@type": "Question", "name": "Les troubles de la peau sont-ils fréquents avec les sphingolipides ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des affections cutanées comme l'eczéma peuvent être liées à des déséquilibres." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon le type de sphingolipide ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes dépendent du type de sphingolipide impliqué et de l'organe affecté." } }, { "@type": "Question", "name": "Peut-on prévenir les maladies liées aux sphingolipides ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un mode de vie sain peut réduire les risques." } }, { "@type": "Question", "name": "Les tests génétiques aident-ils à la prévention ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent identifier les personnes à risque et guider la prévention." } }, { "@type": "Question", "name": "L'éducation sur les sphingolipides est-elle importante ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, comprendre les sphingolipides aide à reconnaître les symptômes et à agir rapidement." } }, { "@type": "Question", "name": "Les habitudes alimentaires influencent-elles la santé des sphingolipides ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation équilibrée peut soutenir la santé des sphingolipides et prévenir des troubles." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider à prévenir des complications ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations peuvent prévenir des infections qui aggravent les troubles liés aux sphingolipides." } }, { "@type": "Question", "name": "Quels traitements existent pour les maladies des sphingolipides ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des thérapies enzymatiques, des médicaments et des soins symptomatiques." } }, { "@type": "Question", "name": "La diète peut-elle influencer les niveaux de sphingolipides ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en acides gras essentiels peut aider à réguler les sphingolipides." } }, { "@type": "Question", "name": "Les médicaments peuvent-ils réduire les symptômes ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments peuvent atténuer les symptômes et améliorer la qualité de vie." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux pour ces maladies ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des essais cliniques explorent de nouvelles thérapies pour les troubles des sphingolipides." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option pour ces maladies ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche pour traiter certaines maladies liées aux sphingolipides." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les troubles des sphingolipides ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles neurologiques graves, des infections et des défaillances organiques." } }, { "@type": "Question", "name": "Les troubles respiratoires sont-ils une complication possible ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles des sphingolipides peuvent entraîner des complications respiratoires." } }, { "@type": "Question", "name": "Comment les sphingolipides affectent-ils le cœur ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des déséquilibres peuvent contribuer à des maladies cardiovasculaires et à des arythmies." } }, { "@type": "Question", "name": "Les complications neurologiques sont-elles fréquentes ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications comme la démence ou des troubles moteurs peuvent survenir." } }, { "@type": "Question", "name": "Les complications peuvent-elles être réversibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque pour les maladies des sphingolipides ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des antécédents familiaux, des mutations génétiques et des déséquilibres nutritionnels." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de troubles des sphingolipides ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains troubles apparaissent plus fréquemment chez les enfants ou les personnes âgées." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies auto-immunes peuvent augmenter le risque de troubles liés aux sphingolipides." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent le risque." } }, { "@type": "Question", "name": "Les infections peuvent-elles aggraver les troubles des sphingolipides ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines infections peuvent exacerber les symptômes et les complications." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 10/03/2025

Contenu vérifié selon les dernières recommandations médicales

Sous-catégories

17 au total
└─

Glycosphingolipides

Glycosphingolipids D006028 - D10.570.877.360
└─└─

Glycosphingolipides acides

Acidic Glycosphingolipids D020384 - D10.570.877.360.025
└─└─

Glycosphingolipides neutres

Neutral Glycosphingolipids D020383 - D10.570.877.360.612
└─└─

Psychosine

Psychosine D011609 - D10.570.877.360.806
└─└─└─

Gangliosides

Gangliosides D005732 - D10.570.877.360.025.475
└─└─└─

Sulfoglycosphingolipides

Sulfoglycosphingolipids D013433 - D10.570.877.360.025.837
└─└─└─

Céramides

Ceramides D002518 - D10.570.877.360.612.200
└─└─└─

Sphingomyéline

Sphingomyelins D013109 - D10.570.877.360.612.870
└─└─└─└─

Ganglioside GM1

G(M1) Ganglioside D005677 - D10.570.877.360.025.475.390
└─└─└─└─

Ganglioside GM2

G(M2) Ganglioside D005678 - D10.570.877.360.025.475.400
└─└─└─└─

Ganglioside GM3

G(M3) Ganglioside D005679 - D10.570.877.360.025.475.510
└─└─└─└─

Cérébrosides

Cerebrosides D002554 - D10.570.877.360.612.200.250
└─└─└─└─

Globosides

Globosides D005915 - D10.570.877.360.612.200.425
└─└─└─└─

Lactosylcéramides

Lactosylceramides D007790 - D10.570.877.360.612.200.612
└─└─└─└─

Trihexosylcéramide

Trihexosylceramides D014281 - D10.570.877.360.612.200.906
└─└─└─└─└─

Galactosylcéramides

Galactosylceramides D005699 - D10.570.877.360.612.200.250.450
└─└─└─└─└─

Glucosylcéramides

Glucosylceramides D005963 - D10.570.877.360.612.200.250.490

Auteurs principaux

Erich Gulbins

3 publications dans cette catégorie

Affiliations :
  • Department of Molecular Biology, University of Duisburg-Essen, Essen, Germany.
  • Department of Surgery, University of Cincinnati, Cincinnati, OH, United States.
Publications dans "Sphingolipides" :

Giovanni D'Angelo

3 publications dans cette catégorie

Affiliations :
  • Interfaculty Institute of Bioengineering, Ecole polytechnique fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland giovanni.dangelo@epfl.ch Christopher.Clarke@stonybrookmedicine.edu lianacsilva@ff.ulisboa.pt.
Publications dans "Sphingolipides" :

Anna Kovilakath

3 publications dans cette catégorie

Affiliations :
  • Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, United States.
Publications dans "Sphingolipides" :

L Ashley Cowart

3 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry and Molecular Biology and the Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.
  • Richmond Veteran's Affairs Medical Center, Richmond, VA, United States.
Publications dans "Sphingolipides" :

Tyrone Dowdy

3 publications dans cette catégorie

Affiliations :
  • Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.
Publications dans "Sphingolipides" :

Mioara Larion

3 publications dans cette catégorie

Affiliations :
  • Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA.
Publications dans "Sphingolipides" :

Anthony H Futerman

2 publications dans cette catégorie

Affiliations :
  • Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
Publications dans "Sphingolipides" :

Burkhard Kleuser

2 publications dans cette catégorie

Affiliations :
  • Department of Toxicology, University of Potsdam, Nuthetal, Germany.
Publications dans "Sphingolipides" :

Fabian Schumacher

2 publications dans cette catégorie

Affiliations :
  • Department of Toxicology, University of Potsdam, Nuthetal, Germany.
  • Department of Molecular Biology, University of Duisburg-Essen, Essen, Germany.
Publications dans "Sphingolipides" :

Hugo J Bellen

2 publications dans cette catégorie

Affiliations :
  • Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States.
  • Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX, United States.
  • Department of Neuroscience, Baylor College of Medicine, Houston, TX, United States.
Publications dans "Sphingolipides" :

Stuart M Pitson

2 publications dans cette catégorie

Affiliations :
  • Centre for Cancer Biology, University of South Australia and SA Pathology, UniSA CRI Building, North Tce, Adelaide, SA 5001, Australia; Adelaide Medical School, University of Adelaide, Adelaide, SA 5001, Australia; School of Biological Sciences, University of Adelaide, Adelaide, SA 5000, Australia. Electronic address: stuart.pitson@unisa.edu.au.
Publications dans "Sphingolipides" :

Melissa Vos

2 publications dans cette catégorie

Affiliations :
  • Institute of Neurogenetics, University of Luebeck, Ratzeburger Allee 160, 23562 Lübeck, Germany.
Publications dans "Sphingolipides" :

Adrian Lita

2 publications dans cette catégorie

Publications dans "Sphingolipides" :

Lumin Zhang

2 publications dans cette catégorie

Publications dans "Sphingolipides" :

Mark R Gilbert

2 publications dans cette catégorie

Publications dans "Sphingolipides" :

Nawajes Mandal

2 publications dans cette catégorie

Affiliations :
  • Department of Ophthalmology, University of Tennessee Health Science Center, UTHSC, Memphis, TN, USA. nmandal@uthsc.edu.
  • Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, UTHSC, Memphis, TN, USA. nmandal@uthsc.edu.

Maryam Jamil

2 publications dans cette catégorie

Affiliations :
  • Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, United States.
  • Department of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.
Publications dans "Sphingolipides" :

Lauren Ashley Cowart

2 publications dans cette catégorie

Affiliations :
  • Department of Biochemistry and Molecular Biology, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, United States.
  • Richmond Veteran's Affairs Medical Center, Richmond, VA, United States.
Publications dans "Sphingolipides" :

Miroslav Machala

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Toxicology, Veterinary Research Institute, Hudcova 296/70, 62100 Brno, Czech Republic.

Jiřina Procházková

2 publications dans cette catégorie

Affiliations :
  • Department of Chemistry and Toxicology, Veterinary Research Institute, Hudcova 296/70, 62100 Brno, Czech Republic.

Sources (10000 au total)

Interactive Learning System for Learning Calculus.

IT tools has brought a new perspective to collaborative learning where students do not just sit in a chair and swallow lecture content but instead participate in creating and sharing knowledge. Howeve... This research develops an interactive application for learning calculus that promotes human-system interaction via augmented reality (AR) and human-human interaction through chat functions. The study ... The research adopted a quasi-experimental study design and pre-post test data analysis to evaluate the effect of interactivities on learning experience and consequently the effect of learning experien... The results found that both interactivities affect learning experience positively; human-human interactivity has a higher impact than the human-system interactivity. It was also found that learning pe...

Lifelong learning in community healthcare: Testing competence after learning activities in a blended learning space.

This study reports from a municipality in Norway that implemented a competence enhancement programme for all its institutional nursing staff during the COVID-19 pandemic to fill identified competence ... Many Norwegian municipalities are experiencing a demand for expanded community healthcare services due to an increase in elderly patients and patients with extensive and complex needs. At the same tim... Nursing staff were encouraged to complete targeted competence enhancing activities with the aim of enhancing their competence in identified areas. The learning activities were blended and consisted of... The results provide insight into the competence development of registered nurses and assistant nurses in institutional community health services. They show that the implementation of a workplace-based... Offering workplace-based competence enhancing activities seems to be a sustainable way of facilitating lifelong learning among nursing staff. Facilitation of learning activities in a blended learning ...

If we assess, will they learn? Students' perspectives on the complexities of assessment-for-learning.

Assessment can positively influence learning, however designing effective assessment-for-learning interventions has proved challenging. We implemented a mandatory assessment-for-learning system compri... We conducted semi-structured interviews with year-3 and 4 medical students at McGill University to explore how the assessment system had influenced their learning in year 3. We conducted theory-inform... Eleven students participated, revealing that the assessment influenced learning through several mechanisms. Some required little student engagement (i.e., feed-up, test-enhanced learning, looking thin... Our assessment system failed to engage students enough to leverage its full potential. We discuss the inherent flaws and external factors that hindered student engagement. Assessment designers should ...